Lipoprotein apheresis for lipoprotein(a)-Associated cardiovascular disease: Prospective 5 years of follow-up and apolipoprotein(a) characterization

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 9, 2016, Pages 2019-2027

  Roeseler, Eberhard ^a   Julius, Ulrich ^b   Heigl, Franz ^c   Spitthoever, Ralf ^d   Heutling, Dennis ^e   Breitenberger, Paul ^f   Leebmann, Josef ^g   Lehmacher, Walter ^h   Kamstrup, Pia R ⁱ   Nordestgaard, Børge G ⁱ   Maerz, Winfried ^j,k   Noureen, Asma ^l   Schmidt, Konrad ^l   Kronenberg, Florian ^l   Heibges, Andreas ^m   Klingel, Reinhard ^m  

^a Hypertension and Metabolic Diseases   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Medical Care Center Kempten Allgäu   (Germany)

^d Dialysis and Lipid Center North Rhine   (Germany)

^e Clinic for Nephrology and Dialysis   (Germany)

^f KfH Kidney Center   (Germany)

^g Department of Trauma Surgery   (Germany)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^m Apheresis Research Institute   (Germany)

more..

Author keywords

Cardiovascular disease; Coronary disease; Lipoprotein apheresis; Lipoprotein(a); Prevention; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; LIPOPROTEIN A;

ADULT; AGED; APHERESIS; ARTICLE; ATHEROSCLEROSIS; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HUMAN; HYPERLIPOPROTEINEMIA; INCIDENCE; IRON THERAPY; LIPID ANALYSIS; LIPOPROTEIN APHERESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK FACTOR; SAFETY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HYPERLIPOPROTEINEMIAS; MIDDLE AGED; PROCEDURES; RISK ASSESSMENT; TIME FACTOR;

AGED; APOPROTEIN(A); BIOMARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; HYPERLIPOPROTEINEMIAS; INCIDENCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84978743384     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307983     Document Type: Article

References (27)

1. Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantner B, Stadler M, Peters A, Koenig W, Stöckl A, Dähnhardt D, Böger CA, Krämer BK, Fraedrich G, Strauch K, Kronenberg F, Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 2014 103 28 36. doi: 10.1093/cvr/cvu107
2. Nordestgaard BG, Chapman MJ, Ray K, European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010 31 2844 2853. doi: 10.1093/eurheartj/ehq386
3. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009 301 2331 2339. doi: 10.1001/jama.2009.801
4. Kronenberg F, Utermann G, Lipoprotein(a): Resurrected by genetics. J Intern Med 2013 273 6 30. doi: 10.1111/j.1365-2796.2012.02592.x
5. Marcovina SM, Albers JJ, Lipoprotein (a) measurements for clinical application. J Lipid Res 2016 57 526 537. doi: 10.1194/jlr.R061648
6. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J, Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010 55 2160 2167. doi: 10.1016/j.jacc.2009.10.080
7. Clarke R, Peden JF, Hopewell JC, PROCARDIS Consortium Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009 361 2518 2528. doi: 10.1056/NEJMoa0902604
8. Thompson GR, HEART-UK LDL Apheresis Working Group Recommendations for the use of LDL apheresis. Atherosclerosis 2008 198 247 255. doi: 10.1016/j.atherosclerosis.2008.02.009
9. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, Mandry P, Marais AD, Matthews S, Neuwirth C, Pottle A, le Roux C, Scullard D, Tyler C, Watkins S, Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010 208 317 321. doi: 10.1016/j.atherosclerosis.2009.06.010
10. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group∗ Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013 128 2567 2576. doi: 10.1161/CIRCULATIONAHA.113.002432
11. Dittrich-Riediger J, Schatz U, Hohenstein B, Julius U, Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Atheroscler Suppl 2015 18 45 52. doi: 10.1016/j.atherosclerosissup.2015.02.007
12. Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R, Efficacy, safety, and tolerability of long-Term lipoprotein apheresis in patients with LDL-or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl 2015 18 154 162. doi: 10.1016/j.atherosclerosissup.2015.02.013
13. Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U, TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients-A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Atheroscler Suppl 2015 18 199 208. doi: 10.1016/j.atherosclerosissup.2015.02.030
14. Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H, Lipoprotein(a)-And low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004 66 348 354. doi: 10.1111/j.1523-1755.2004.00737.x
15. Yeang C, Witztum JL, Tsimikas S, 'LDL-C' = LDL-C + Lp(a)-C: Implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 2015 26 169 178. doi: 10.1097/MOL.0000000000000171
16. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J, Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. Circulation 1999 100 1154 1160
17. Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF, Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clin Ther 2012 34 1387 1394. doi: 10.1016/j.clinthera.2012.04.004
18. Kronenberg F, Genetic determination of lipoprotein(a) and its association with cardiovascular disease: Convenient does not always mean better. J Intern Med 2014 276 243 247. doi: 10.1111/joim.12207
19. Arai K, Orsoni A, Mallat Z, Tedgui A, Witztum JL, Bruckert E, Tselepis AD, Chapman MJ, Tsimikas S, Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 2012 53 1670 1678. doi: 10.1194/jlr.P027235
20. Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, de Lemos JA, Witztum JL, Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: Results from the Dallas Heart Study. Circulation 2009 119 1711 1719. doi: 10.1161/CIRCULATIONAHA.108.836940
21. Wu HD, Berglund L, Dimayuga C, Jones J, Sciacca RR, Di Tullio MR, Homma S, High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol 2004 43 1828 1833. doi: 10.1016/j.jacc.2003.08.066
22. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T, Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997 95 76 82
23. Galle J, Bengen J, Schollmeyer P, Wanner C, Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation 1995 92 1582 1589
24. Grimm JM, Nikolaou K, Schindler A, Hettich R, Heigl F, Cyran CC, Schwarz F, Klingel R, Karpinska A, Yuan C, Dichgans M, Reiser MF, Saam T, Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR-A comparative analysis. J Cardiovasc Magn Reson 2012 14 80. doi: 10.1186/1532-429X-14-80
25. Libby P, Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013 368 2004 2013. doi: 10.1056/NEJMra1216063
26. Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS, AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013 128 962 969. doi: 10.1161/CIRCULATIONAHA.113.001969
27. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL, Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015 386 1472 1483. doi: 10.1016/S0140-6736(15)61252-1